WT1 Mutation Does Not Influence Transplantation Outcomes for Acute Myeloid Leukemia

Research has been conducted to study the impact of Wilms' tumor 1 gene (WT1) mutation on outcomes of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia (AML). A study published in Bone Marrow Transplantation compared the outcomes of 703 patients with WT1 mutation (mWT1) to those with wild-type WT1 AML (wtWT1). The results showed that patients with mWT1 were younger, but the WT1 mutation did not influence transplantation outcomes in patients in complete remission (CR1). The study used data from the ALWP/EBMT registry and was conducted at Sheba Medical Center in Tel-Hashomer, Israel.

Key Takeaways:

The study included 703 patients, 50 with WT1 mutation (mWT1) and 653 with wild-type WT1 AML (wtWT1).
Patients with mWT1 were younger, with a median age of 45.6 years, compared to 56.4 years for patients with wtWT1 (p=0.008).
WT1 mutation did not influence transplantation outcomes of AML patients in CR1.
The study used data from the ALWP/EBMT registry, a retrospective multicenter cohort study.
The research was conducted at Sheba Medical Center in Tel-Hashomer, Israel.

Statistics:

703 patients were included in the study.
50 patients had WT1 mutation (mWT1).
653 patients had wild-type WT1 AML (wtWT1).
Median age of patients with mWT1 was 45.6 years.
Median age of patients with wtWT1 was 56.4 years.

Sources:

NewsRx. Researchers at Sheba Medical Center Target Acute Myeloid Leukemia [Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from ...]. Hematology Week. October 27, 2025; p 1699.
Bone Marrow Transplantation. Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry. Bone Marrow Transplantation, 2025.